EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways

Vanshika Garg, Raphael N H M Hofmann, Moazzam Saleem iD, Amin Mirzaiebadizi iD, Ghazaleh Sadat Hashemi, Tooba Hameed, Bahareh Jooyeh, Silke Pudewell iD, Mehrnaz Mehrabipour, Niloufar Mosaddeghzadeh, Roland P Piekorz, Mohammad Reza Ahmadian iD

Cells · 20.01.2026 · 15 (2) · 190

DOI: 10.3390/cells15020190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 20.01.2026. Verfasst von Vanshika Garg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 402…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Signal Transduction, Carcinogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, the European Network on Noonan Syndrome and Related Disorders (NSEuroNet), German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oncogene KRAS drives tumor growth by activating pathways such as MAPK and PI3K-AKT in a constitutive manner. Although direct KRAS inhibitors exist, they are often limited in clinical use due to therapeutic resistance and toxicity. Therefore, alternative combinatorial therapeutic strategies are urgently needed. This study examined the knockout of five KRAS-related proteins—galectin-3 (GAL3), phosphodiesterase delta (PDEδ), nucleophosmin (NPM1), IQ motif-containing GTPase-activating protein 1 (IQGAP1), and SHOC2—using CRISPR-Cas9 in adenocarcinoma cell lines harboring the KRAS(G12V) oncogenic mutation, as well as in the noncancerous HEK-293 cell line. These proteins act as critical modulators that regulate KRAS activity, cellular localization, and that of its downstream signaling components. We analyzed the downstream activation of ERK and AKT kinases and evaluated subsequent cancer cell proliferation. Knockout of GAL3 and PDEδ was highly effective, significantly reducing MAPK and PI3K-AKT pathway activity and substantially impairing cell proliferation. SHOC2 knockout selectively and potently disrupted MAPK activation, while NPM1 knockout resulted in the complex, reciprocal modulation of the two major pathways. Notably, knocking out IQGAP1 enhanced PI3K–AKT and mTORC2–AKT signaling without affecting the MAPK pathway. These distinct modulatory roles highlight the non-redundant functions of the accessory proteins. In conclusion, our findings establish GAL3 and PDEδ, two KRAS-associated proteins, as promising combinatorial drug targets. Targeting these modulators provides an effective alternative strategy to overcome resistance mechanisms and enhance the clinical utility of existing KRAS inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Signal TransductionCarcinogenesisHumansNucleophosminProto-Oncogene Proteins c-aktCell Proliferationras GTPase-Activating ProteinsHEK293 CellsCell Line, TumorPhosphatidylinositol 3-KinasesGalectin 3Nuclear Proteins

Stichwörter der Autor:innen

AKTGalectin-3IQGAP1KRAS oncogeneMAPKPDE-deltaSHOC2accessory proteinsadenocarcinomanucleophosminsignal transduction

Substanzen

NucleophosminProto-Oncogene Proteins p21(ras)NPM1 protein, humanProto-Oncogene Proteins c-aktKRAS protein, humanras GTPase-Activating ProteinsPhosphatidylinositol 3-KinasesGalectin 3Nuclear ProteinsIQ motif containing GTPase activating protein 1

Autor:innen und Institutionen

  • Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, Building 22.03, 40225 Düsseldorf, Germany.

ORCID-Profile: Moazzam Saleem, Amin Mirzaiebadizi, Silke Pudewell, Mohammad Reza Ahmadian

Förderung

  • Deutsche Forschungsgemeinschaft
  • the European Network on Noonan Syndrome and Related Disorders (NSEuroNet)
  • German Research Foundation
  • European Network on Noonan Syndrome and Related Disorders

Zitieren

APA

Garg, V., Hofmann, R. N. H. M., Saleem, M., Mirzaiebadizi, A., Hashemi, G. S., Hameed, T., Jooyeh, B., Pudewell, S., Mehrabipour, M., Mosaddeghzadeh, N., Piekorz, R. P., & Ahmadian, M. R. (2026). Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. Cells, 15(2), 190. https://doi.org/10.3390/cells15020190

Vancouver

Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, et al. Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. Cells. 2026;15(2):190. doi:10.3390/cells15020190

BibTeX
@article{Garg2026,
  author = {Garg, Vanshika and Hofmann, Raphael N H M and Saleem, Moazzam and Mirzaiebadizi, Amin and Hashemi, Ghazaleh Sadat and Hameed, Tooba and Jooyeh, Bahareh and Pudewell, Silke and Mehrabipour, Mehrnaz and Mosaddeghzadeh, Niloufar and Piekorz, Roland P and Ahmadian, Mohammad Reza},
  title = {Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {190},
  doi = {10.3390/cells15020190}
}
Kostenlos starten →